20/20 Biolabs Inc AIDX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
20/20 BioLabs to Participate in the Maxim Growth Summit 2026 in New York on October 14, 2026
-
20/20 BioLabs to Host Investor Webinar on October 7, 2026 to Discuss FDA Advisory Committee Vote and New OneTest™ Franchise Model
-
20/20 BioLabs Reschedules Investor Webinar to 2:00 p.m. Eastern Time on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
-
20/20 BioLabs to Host Investor Webinar on September 2, 2026 to Discuss OneTest™ Revenue and Expanding Commercial Opportunity
-
20/20 BioLabs Reports Second Quarter 2026 Financial Results and Recent Operational Progress, as Cancer Test Revenue Reaches Record Quarterly Level
-
20/20 BioLabs to Host Investor Webinar on August 5, 2026, to Discuss Commercial Opportunities Following Management’s Recent East Asia Business Development Tour
-
20/20 BioLabs Participates in BIO Asia-Taiwan and Meets with Strategic Counterparties in Taipei, Tokyo, and Seoul to Advance East Asia Roll-Up Strategy
-
Correction to AbbVie Article on April 20
Trading Information
- Previous Close Price
- $0.25
- Day Range
- $0.24–0.27
- 52-Week Range
- $0.24–50.00
- Bid/Ask
- $0.24 / $0.24
- Shares Outstanding
- 12.77M
- Market Cap
- $3.00M
- Volume/Avg
- 191,526 / 101,180
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.20
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- —
- Total Number of Employees
- 14
- Website
- https://www.2020biolabs.com
Valuation
|
Metric
|
AIDX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.90 |
Price/Sales | 1.20 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
AIDX
|
|---|---|
Quick Ratio | 1.90 |
Current Ratio | 1.99 |
Interest Coverage | −7.42 |
Quick Ratio
AIDX
Profitability
|
Metric
|
AIDX
|
|---|---|
Return on Assets (Normalized) | −101.05% |
Return on Equity (Normalized) | −467.93% |
Return on Invested Capital (Normalized) | −198.55% |
Return on Assets
AIDX
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|lmwWVrD | LOCK|$^&M | $179B | |||
| Medtronic PLC
MDT
| LOCK|>nq^wZP | LOCK|SXLj | $122B | |||
| Stryker Corp
SYK
| LOCK|!<XKC<G | LOCK|b& | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|Dcs?@?Y | LOCK|P%?z | $66B | |||
| Edwards Lifesciences Corp
EW
| LOCK|>#RqG@v | LOCK|#%@fL | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|<ddXG@C | LOCK|@& | $32B | |||
| DexCom Inc
DXCM
| LOCK|X^Gpn!VB | LOCK|@!f&R | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|BV# | LOCK|sP | $26B | |||
| Steris PLC
STE
| LOCK|dxN<@$ | LOCK|%p>l@ | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|tyK!V@# | LOCK|^$P | $19B |
United States